Wedbush Increases Earnings Estimates for IDEAYA Biosciences

Key Points

• Wedbush raised its earnings estimates for IDEAYA Biosciences, projecting $1.37 earnings per share for Q3 2025, up from a previous estimate of ($0.94).
• IDEAYA reported a quarterly loss of ($0.88) EPS, slightly missing analyst expectations, but achieved revenues of $6.00 million compared to a consensus of $3.48 million.
• Investment firms like JPMorgan and Goldman Sachs have recently adjusted their price targets and ratings for IDEAYA Biosciences, with the average target price now around $47.30.

IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) - Investment analysts at Wedbush lifted their Q3 2025 earnings per share estimates for shares of IDEAYA Biosciences in a research report issued on Tuesday, September 2nd. Wedbush analyst R. Driscoll now expects that the company will earn $1.37 per share for the quarter, up from their previous estimate of ($0.94). The consensus estimate for IDEAYA Biosciences' current full-year earnings is ($3.07) per share. Wedbush also issued estimates for IDEAYA Biosciences' FY2025 earnings at ($1.29) EPS, Q1 2026 earnings at ($1.03) EPS, Q2 2026 earnings at ($1.07) EPS, Q3 2026 earnings at ($1.10) EPS, Q4 2026 earnings at ($0.56) EPS, FY2026 earnings at ($3.77) EPS, FY2027 earnings at ($3.48) EPS, FY2028 earnings at ($3.13) EPS and FY2029 earnings at ($0.77) EPS.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.85) by ($0.03). The business had revenue of $6.00 million during the quarter, compared to the consensus estimate of $3.48 million. IDEAYA Biosciences's quarterly revenue was up NaN% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.68) earnings per share.

IDYA has been the topic of a number of other research reports. JPMorgan Chase & Co. increased their price target on IDEAYA Biosciences from $72.00 to $74.00 and gave the company an "overweight" rating in a research report on Wednesday. The Goldman Sachs Group raised IDEAYA Biosciences to a "hold" rating and set a $25.00 price target on the stock in a research report on Thursday, July 10th. TD Cowen started coverage on IDEAYA Biosciences in a report on Tuesday, July 22nd. They issued a "buy" rating on the stock. Wells Fargo & Company started coverage on IDEAYA Biosciences in a report on Thursday, June 26th. They issued an "overweight" rating and a $44.00 price objective on the stock. Finally, Royal Bank Of Canada upgraded IDEAYA Biosciences from an "outperform" rating to a "moderate buy" rating and dropped their price objective for the company from $57.00 to $30.00 in a report on Wednesday, July 9th. Nine investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $47.30.

IDEAYA Biosciences Price Performance

IDYA stock opened at $25.76 on Thursday. The firm has a market capitalization of $2.26 billion, a P/E ratio of -6.80 and a beta of 0.12. The business's 50-day moving average is $23.47 and its two-hundred day moving average is $20.56. IDEAYA Biosciences has a 1 year low of $13.45 and a 1 year high of $39.30.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Janus Henderson Group PLC grew its stake in shares of IDEAYA Biosciences by 13.5% in the 4th quarter. Janus Henderson Group PLC now owns 5,857,639 shares of the company's stock valued at $150,606,000 after purchasing an additional 695,263 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of IDEAYA Biosciences by 0.3% in the 1st quarter. Vanguard Group Inc. now owns 5,092,619 shares of the company's stock valued at $83,417,000 after purchasing an additional 14,535 shares during the last quarter. Deerfield Management Company L.P. Series C grew its stake in shares of IDEAYA Biosciences by 5.5% in the 4th quarter. Deerfield Management Company L.P. Series C now owns 2,736,000 shares of the company's stock valued at $70,315,000 after purchasing an additional 142,000 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of IDEAYA Biosciences by 1.6% in the 2nd quarter. Geode Capital Management LLC now owns 2,113,164 shares of the company's stock valued at $44,424,000 after purchasing an additional 33,286 shares during the last quarter. Finally, Fiera Capital Corp grew its stake in shares of IDEAYA Biosciences by 26.6% in the 2nd quarter. Fiera Capital Corp now owns 1,532,269 shares of the company's stock valued at $32,208,000 after purchasing an additional 322,404 shares during the last quarter. Hedge funds and other institutional investors own 98.29% of the company's stock.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.